RELX-INTERNATIONAL
17.5.2022 15:28:06 CEST | Business Wire | Press release
RELX International, a responsible multinational electronic cigarettes company, is urging decision-makers in Morocco and Algeria to roll out comprehensive regulatory frameworks for e-cigarettes, ahead of an expected surge in smoking habits. Longstanding research has shown that smoking traditional, tobacco-based cigarettes poses significant health risks.
According to data compiled by website GSTHR.org (Global State of Tobacco Harm Reduction), there has been an upward trend in current smoking prevalence in the general population in Morocco.
In 2015, overall prevalence was estimated to be 23%, with a projection to increase to 28% by 2025 in Morocco. [1]. While in Algeria, current smoking trends for the overall adult population is also projected to increase, with an estimate of 16.9% by 2025 as per GSTHR.org. [2].
In contrast to traditional cigarettes, e-cigarettes are increasingly being hailed as a better alternative and can even help adult smokers reduce or quit smoking entirely according to several organisations, including the UK’s National Health Service (NHS). The service has found that e-cigarettes are around 95% less harmful than tobacco and have the potential to help smokers quit entirely [3]. A first of its kind clinical trial conducted by the Queen Mary University of London also found e-cigarettes are almost twice as effective as nicotine replacement treatments, such as patches and gum, at helping smokers to quit [4].
As more governments and health authorities endorse the benefits of e-cigarettes based on scientific testing – and given the expected increase in smoking habits in Morocco and Algeria, authorities should roll out risk-proportionate regulatory frameworks to govern the import, marketing and distribution of e-cigarettes. By doing so, adult smokers in both countries will have access to quality products from brands such as RELX that comply with international and local quality and safety health regulations, are priced accessibly, and are imported and distributed legally, in support of the economy.
Should these markets remain unregulated, it is likely that illicit trade will grow significantly, and see the markets seeded with counterfeit products of questionable quality. These products could pose a significant risk to smokers’ health and could end up in the hands of those under the legal age.
Links:
[1] Smoking, vaping, HTP, NRT and snus in Morocco
[2] Smoking, vaping, HTP, NRT and snus in Algeria
[3] E-cigarettes around 95% less harmful than tobacco estimates landmark review
[4] E-cigarettes more effective than nicotine replacement therapies, finds major UK clinical trial
[5] CBP, FDA Seize Counterfeit, Unauthorized E-Cigarettes
Notes to Editors
RELX International
Founded in 2019, RELX International is a multinational electronic cigarettes company that markets and sells RELX, The World’s Advanced vape brand powered by SuperSmooth™ technology. RELX, Asia’s leading e-cigarette brand, is widening its footprint across the world, and it is currently available in 40+ countries such as the UK, France, Italy, Germany, Indonesia, Philippines, Canada, KSA and the UAE. What sets RELX apart from competition is the fact that it has a full ecosystem (such as closed pods, disposables, device, and power bank accessories) that are designed at a cutting-edge research and development center and produced at one of the world’s largest e-cigarette factories. RELX's mission is to make RELX a trusted brand for legal age adult smokers through state-of-the-art products, industry-leading technologies, and scientific advances in collaboration with talented and committed people around the globe. The company has attracted global talents from Uber, Procter & Gamble, Apple, Beats, and L'Oréal. RELX is proud to be listed in Dubai Duty Free, the first duty free channel in the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516006137/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
